Abstract 2649: Isolation and characterization of novel murine mammary cell line with dormant phenotype and identification of new potential targets by mass spectrometry

• Published in: Cancer research (Chicago, Ill.) Ill.), 2020-08, Vol.80 (16_Supplement), p.2649-2649
• Main Authors: Sidabra, Johanna E., Capobianco, Carla S., Gottardo, Maria F., Alonso, Daniel F., Farina, Hernan G.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2020-2649

Breast cancer is the first cause of death from female cancer. After treatments against the primary tumor, a few cells can prevail in a dormant state for a long period, becoming minimal residual disease. These cells can resume growth and establish as metastasis, which are responsible for 90% of deaths from cancer. Patients with breast cancer diagnosed at early stage with small tumours have a 25-30% chance of recurrence after 10-15 years after treatment. These new growth often entails chemo and radio resistance and there is not response to conventional treatment. For all these reasons, there is a clear need for the development of novel therapies against these cells in a dormant state. The main limitation on the study of these dormant cells is the lack of relevant in vitro an in vivo models. In this work, we isolated and characterized two novel cell lines F3II-TP and F3II-NM. F3II-TP represents tumours with high proliferation rate whereas F3II-NM represents a dormant cell phenotype. The comparison between these cell lines is expected to yield new molecular targets for the design of new drugs that point dormant cells. The study began with the isolation and establishment of new tumour cell lines. After inoculation of the F3II murine mammary carcinoma cell line, we established cell populations in vitro, one from the primary tumour and another from a spontaneous metastatic nodule, F3II TP and F3II NM cell lines respectively. First, we analysed the expression of EMT markers such as E-cadherin, N-cadherin, Vimentin, Pan-Cytoqueratin and β-catenin by immunofluorescence. In in vitro assays, F3II NM presented major doubling time, major adhesion capacity and lower clonogenic potential. In addition, the expression of the dormancy related genes such as NR2F1 and BHLHE41 was analysed by qPCR, and we found that F3II-NM showed higher levels of transcript than F3II-TP. In addition, F3II NM showed lower chemo sensibility to cisplatin and in an orthotopic model of BALB/c mice, presented a longer latency time and lower tumour growth rate in comparison to F3II-TP. Taking all these together, F3II NM present a dormant phenotype and F3II TP a proliferative one. Finally, analysis and comparison of the cell lines using LFQ-Mass spectrometry revealed 256 differentially expressed proteins between the lines studied. Overexpressed genes of survival paths were identified in F3II-NM, such as DDX42, COX-2, ATGB4 involved in the inhibition of apoptosis, promotion of tumour recurrence via SOX